Channel Medsystems Announces Grant Support for an Investigator-Sponsored Clinical Study Evaluating Cerene® Cryotherapy for Women With Adenomyosis

Channel Medsystems has provided grant support for a clinical study at NYU Langone Health to evaluate the Cerene® Cryotherapy Device for treating adenomyosis. The study aims to assess the device's effectiveness in reducing pelvic pain and heavy menstrual bleeding.
Why it matters
Advancements in non-invasive gynecological treatments can significantly improve quality of life for women suffering from chronic uterine conditions.
BERKELEY, Calif., Nov. 11, 2026 (GLOBE NEWSWIRE) -- Channel Medsystems, Inc., a privately held medical technology company dedicated to raising the standard of care for women with heavy menstrual bleeding and dysmenorrhea, announced today grant support for an investigator-sponsored study (ISS) at NYU Langone Health’s Center for Fibroid Care evaluating the Cerene® Cryotherapy Device in women with MRI-confirmed adenomyosis.
The study, under the independent direction of Principal Investigator Taraneh Shirazian, M.D., Director of the Center for Fibroid Care at NYU Langone Health, has enrolled its first patients, marking an important milestone and alignment with Channel Medsystems’ scientific and clinical initiatives. The investment to support investigator-sponsored research is part of the company’s broader clinical strategy and is bolstered by its ongoing Series C financing, which recently reached a $30 million milestone.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in